Navigation Links
Genoptix Announces Participation at the BIOCOM Investor Conference 2008
Date:10/22/2008

CARLSBAD, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the BIOCOM Investor Conference 2008 scheduled to take place at the Hyatt Regency in La Jolla, CA on October 26-28, 2008.

Dr. Tina Nova, President and CEO of Genoptix, will present at the conference on Monday, October 27, beginning at approximately 9:30 a.m. PDT. Dr. Nova will provide an overview of the Company's specialized diagnostic laboratory service offerings, growth strategies and past operational performance.

The presentation is expected to last approximately 20 minutes, followed by a 5 minute question and answer session. The presentation will be webcast live and made accessible through the investor relations section of the Genoptix website at http://www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. A replay will also be available for 30 days following the initial presentation web cast.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community- based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genoptix Announces Participation at the UBS Global Life Sciences Conference
2. Genoptix Reports Strong Financial Results For Third Quarter 2007
3. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
6. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
8. Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
9. Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call
10. NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc.
11. BioElectronics Announces Significant Progress in Canadian and International Distribution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... NY (PRWEB) , ... May 26, 2016 , ... ... decades. FireflySci cuvettes are used in leading laboratories all over the globe. ... day. , In addition to manufacturing awesome cuvettes, FireflySci makes spectrophotometer calibration standards ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... features a variety of fracture-specific plating options designed to address fractures of the ... fracture fixation solutions. , The Acumed Ankle Plating System 3 is composed of ...
(Date:5/25/2016)... ... , ... Scientists at the University of Athens say they have evidence that ... the research that could lead to one good one. Surviving Mesothelioma has just posted ... , The team evaluated 98 mesothelioma patients who got a second kind ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Food and Drug Administration (FDA) has granted the company’s orphan drug designation request ... second orphan drug designation granted by the FDA. , Spinocerebellar ataxia is ...
Breaking Biology Technology:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):